SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) |
6 Months Ended |
|---|---|
Jun. 27, 2026 | |
| Accounting Policies [Abstract] | |
| Basis of Presentation | Basis of Presentation Our unaudited Condensed Consolidated Financial Statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2025 (“2025 Form 10-K”).
|
| Principles of Consolidation | In the opinion of management, all adjustments considered necessary for a fair presentation of the unaudited Condensed Consolidated Financial Statements have been included and include our accounts and accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Some amounts in this report may not add due to rounding. |
| Segment Reporting | Segment Reporting Our segments reflect the way in which our chief operating decision maker (“CODM”), who is our Chief Executive Officer (“CEO”), makes operating decisions, allocates resources and manages the growth and profitability of the Company. Financial information related to our business segments and geographic locations can be found in Note 2 and Note 17. In the first quarter of 2026, we completed the implementation of a new operating model intended to further enhance the execution of our strategy and prior period segment disclosures have been revised to reflect the new segments. We now report results in the following three reporting segments: •Self Care is comprised of our Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. •Specialty Care is comprised of our Women's Health and Skin Health product categories globally. •Infant Formula is comprised of the Infant Formula product category, which includes nutrition products designed to meet the dietary needs of infants. Our Oral Care product category and Other product category, which includes our Dermacosmetics Business (refer to Note 3), are together disclosed as “All Other.” We previously had an Rx segment which was comprised of our generic prescription pharmaceuticals business in the U.S., and other pharmaceuticals and diagnostic business in Israel, which have been divested. Following the divestiture, there were no substantial assets or operations left in this segment. The Rx segment was reported as Discontinued Operations in 2021, and is presented as such for all periods in this report (refer to Note 4).
|
| Foreign Currency Translation and Transactions | Foreign Currency Translation and Transactions We translate our non-U.S. dollar-denominated operations’ assets and liabilities into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in the cumulative translation account, a component of Accumulated other comprehensive income (loss) (“AOCI”). Gains or losses from foreign currency transactions are included in Other (income) expense, net.
|
| Allowance for Credit Losses | Allowance for Credit Losses Expected credit losses on trade receivables and contract assets are measured collectively by geographic location. Historical credit loss experience provides the primary basis for estimation of expected credit losses and is adjusted for current conditions and for reasonable and supportable forecasts. Receivables that do not share risk characteristics are evaluated on an individual basis and are not included in the collective evaluation.
|